848592-56-3

Basic information

• Product Name: Pyrrolo[3,4-c]pyrrole-2(1H)-carboxylic acid, hexahydro-5-(3-methoxyphenyl)-, 1,1-dimethylethyl ester
• CAS NO: 848592-56-3
• Molecular Formula: C18H26N2O3
• Molecular Weight: 318.416
• Mol File: 848592-56-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Pyrrolo[3,4-c]pyrrole-2(1H)-carboxylic acid, hexahydro-5-(3-methoxyphenyl)-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Pyrrolo[3,4-c]pyrrole-2(1H)-carboxylic acid, hexahydro-5-(3-methoxyphenyl)-, 1,1-dimethylethyl ester(848592-56-3)
• EPA Substance Registry System: Pyrrolo[3,4-c]pyrrole-2(1H)-carboxylic acid, hexahydro-5-(3-methoxyphenyl)-, 1,1-dimethylethyl ester(848592-56-3)

Safety Data

• Hazardous Substances Data: 848592-56-3(Hazardous Substances Data)

Upstream product

• 141449-85-6 tert-butyl hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate 
• 2398-37-0 3-methoxyphenyl bromide 

Downstream Products

• 848592-57-4 5-(4-iodo-3-methoxy-phenyl)-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic acid tert-butyl ester 

Relevant articles and documents

NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE

Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of sigma- 2 receptor activity.

Substituted diazabicycloalkane derivatives

Compounds of formula (I) [in-line-formulae]Z-Ar1—Ar2??(I) [/in-line-formulae] wherein Z is a diazabicyclic amine, Ar1 is a 5- or 6-membered aromatic ring, and Ar2 is selected from the group consisting of an unsubstituted or substituted 5- or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazolyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.